Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 30;14:3867. doi: 10.1038/s41467-023-39563-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2025

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Analysis of Lamin-SS and Lamin-TM sFRET (mean ± SEM) after cell cycle synchronization to early S-phase (Aphidicolin, 3 µg/mL, 24 h) (n = 10-15 fields, three biological replicates). Ordinary one-way ANOVA Tukey’s multiple comparisons (for Lamin-SS (*) p = 0.0229 and Lamin-TM (ns) p = 0.9619). b, Analysis of Lamin-SS and Lamin-TM sFRET (mean ± SEM) after EMT induction by growth factor treatment (TGF-β1, 2 ng/mL, 24 h) (n = 10 fields, two biological replicates). Ordinary one-way ANOVA Tukey’s multiple comparisons (for Lamin-SS (*) p = 0.0311 and Lamin-TM (ns) p = 0.9666). c Analysis of Lamin-SS and Lamin-TM efficiency (mean ± SEM) after treatment by histone deacetylase inhibitor (TSA, 200 nM, 4 h; n = 10 fields, three biological replicates). Ordinary one-way ANOVA Tukey’s multiple comparisons (for Lamin-SS (****) p < 0.0001 and Lamin-TM (ns) p = 0.4804. d Analysis of Lamin-SS and Lamin-TM (mean ± SEM) efficiency after treatment by histone demethylase inhibitor (methylstat, 2.5 µM, 48 h) of the cells (n = 10–15 fields, two biological replicates). Ordinary one-way ANOVA Tukey’s multiple comparisons (for Lamin-SS (ns) p = 0.2282 and Lamin-TM (ns) p = 0.9584). e Localization of epitopes for the used lamin A/C rod-domain and C-terminal antibodies. The C-terminal epitope accessibility depends on lamin filament organization. f Analysis of nuclear lamina organization in TSA-treated cells. Confocal microscopy maximum intensity projections (CM-MIP) of control (upper panels) and TSA-treated (600 nM, 4 h, lower panels) Lamin-SS expressing cells, immunolabeled against lamin A/C. Quantified fluorescence intensity ratio of lamin A/C labeling in control and TSA-treated cells (box from 25th to 75th percentile, median, whiskers from min to max, n = 15 fields, three biological replicates). Unpaired two-tailed Student’s t test ((ns) p = 0.6, t = 0.5, df=28). g Analysis of lamina organization in methylstat-treated cells. CM-MIP of control (upper panels) and methylstat -treated (2.5 µM, 48 h, lower panels) Lamin-SS expressing cells, immunolabeled against lamin A/C. Quantified fluorescence intensity ratio of lamin A/C labeling (box from 25th to 75th percentile, median, whiskers form min to max, n = 15 fields, 3 biological replicates). Unpaired two-tailed Student’s t test ((ns) p = 0.4, t = 0.9, df = 28). h Summary table of the relative changes in the quantified FRET changes in different conditions. Scale bars, a–d 20 µm and f–g 10 µm.